

United States Court of Appeals
for the Federal Circuit

ALLERGAN, INC.,
Plaintiff-Appellee

v.

SANDOZ INC., LUPIN LTD., LUPIN
PHARMACEUTICALS, INC., HI-TECH
PHARMACAL CO., INC.,
Defendants-Appellants

2014-1275

Appeal from the United States District Court for the
Eastern District of Texas in No. 6:11-cv-00441-MHS,
Judge Michael H. Schneider.

Decided: August 4, 2015

JUANITA ROSE BROOKS, Fish & Richardson, P.C., San
Diego, CA, argued for plaintiff-appellee. Also represented
by CRAIG E. COUNTRYMAN; JONATHAN ELLIOT SINGER,
DEANNA JEAN REICHEL, Minneapolis, MN; DOUGLAS E.
McCANN, SUSAN M. COLETTI, Wilmington, DE.

DEANNE MAYNARD, Morrison & Foerster LLP, Wash-
ington, DC, argued for defendant-appellant Sandoz Inc.
Also represented by BRIAN ROBERT MATSUI; DAVID

CLARENCE DOYLE, ANDERS T. AANNESTAD, JAMES CEKOLA,
San Diego, CA.

WILLIAM A. RAKOCZY, Rakoczy Molino Mazzochi,
Siwik LLP, Chicago, IL, argued for defendants-appellants
Lupin Ltd., Lupin Pharmaceuticals, Inc. Also represented
by PAUL J. MOLINO, DEANNE M. MAZZOCHI, THEODORE
JOSEPH CHIACCHIO, JOHN POLIVICK.

STEVEN D. ROTH, Locke Lord, LLP, New York, NY, ar-
gued for defendant-appellant Hi-Tech Pharmcal Co., Inc.
Also represented by THOMAS J. VETTER, Lucas & Mer-
canti, LLP, New York, NY.

Before LOURIE, LINN, and HUGHES, *Circuit Judges*.

LOURIE, *Circuit Judge*.

Sandoz Inc. (“Sandoz”), Lupin Ltd. and Lupin Phar-
maceuticals, Inc. (collectively, “Lupin”), and Hi-Tech
Pharmcal Co., Inc. (“Hi-Tech”) (collectively, “the Appel-
lants”)¹ appeal from the decision of the United States
District Court for the Eastern District of Texas, following
a bench trial, which held that the claims of U.S. Patents
7,851,504 (the “’504 patent”), 8,278,353 (the “’353 pa-
tent”), 8,299,118 (the “’118 patent”), 8,309,605 (the “’605
patent”), and 8,338,479 (the “’479 patent”), asserted by
Allergan, Inc. (“Allergan”), were not shown to be invalid
for obviousness under 35 U.S.C. § 103, and that the

¹ Watson Laboratories, Inc., Watson Pharmaceuti-
cals, Inc., and Watson Pharm, Inc. (collectively, “Watson”)
were also defendants-appellants initially. But Watson
has since been dismissed from this appeal on a joint
motion filed by Watson and Allergan. *See Allergan, Inc. v.*
Sandoz Inc., No. 14-1275, ECF No. 121 (Fed. Cir. Apr. 17,
2015).

claims of the '353 and '118 patents were not shown to be invalid for lack of an adequate written description under 35 U.S.C. § 112, ¶ 1.² *Allergan, Inc. v. Sandoz Inc.*, No. 6:11-cv-00441, ECF No. 303, slip op. at 77, 79 (E.D. Tex. Jan. 13, 2014) (“*Opinion*”). Additionally, Lupin challenges the district court’s determination that the claims of Allergan’s patents were not shown to be invalid for lack of enablement under § 112, ¶ 1. *Id.* at 80–81. Hi-Tech also challenges the district court’s finding that it infringed the claims of the '504, '605, and '479 patents literally and under the doctrine of equivalents. *Id.* at 64–66. For the reasons that follow, we *affirm* in all respects.

BACKGROUND

I

Glaucoma is an eye disease associated with elevated intraocular pressure (“IOP”). Treatments that effectively reduce IOP can slow the progression of the disease. If left untreated, however, elevated IOP can damage the optic nerve and lead to permanent vision loss and blindness. In 2001, the U.S. Food and Drug Administration (the “FDA”) approved Lumigan® 0.03% (“Lumigan 0.03%”), a once-daily topical solution developed by Allergan, for treating open angle glaucoma and ocular hypertension. Lumigan 0.03% contains 0.03% by weight of bimatoprost and 50 parts per million (“ppm”) benzalkonium chloride (“BAK”), among other ingredients.

Bimatoprost, the active ingredient in Lumigan 0.03%, is a prostaglandin analog that effectively lowers IOP, but can cause hyperemia, *i.e.*, red eye, when administered to

² Because the applications resulting in the patents asserted in this case were filed before the enactment of the Leahy-Smith America Invents Act (“AIA”), Pub. L. No. 112-29, 125 Stat. 284 (2011), we apply the pre-AIA version of 35 U.S.C. § 103 and § 112.

the ocular surface. One structural difference between bimatoprost and two other prostaglandin analogs that were approved for treating glaucoma at the time of its approval, Xalatan® (latanoprost) and Travatan® (travoprost), is that bimatoprost contains an amide, instead of an ester as in latanoprost and travoprost. *Opinion* at 7–8. It was understood that both latanoprost and travoprost, but not bimatoprost, act as prodrugs of the corresponding acids. *Id.*

BAK is a preservative for inhibiting bacterial growth in ophthalmic solutions. It was known, however, that BAK is cytotoxic and that it can damage the cells on the ocular surface and cause undesirable side effects.

Although Lumigan 0.03% was effective at lowering IOP, it also caused frequent and severe hyperemia. Many patients thus stopped using it without consulting their physicians, which led to gradual vision loss. To address that problem, Allergan explored a number of alternative formulations of bimatoprost and surprisingly discovered that increasing the concentration of BAK from 50 ppm to 200 ppm significantly increased the corneal permeability of bimatoprost. *Id.* at 12–13. After further research, Allergan developed Lumigan® 0.01% (“Lumigan 0.01%”).

Lumigan 0.01% is a topical solution containing 0.01% bimatoprost and 200 ppm BAK; otherwise, it has the same ingredients as Lumigan 0.03%. Thus, as compared with Lumigan 0.03%, Lumigan 0.01% has a three-fold lower bimatoprost concentration and a four-fold higher BAK concentration. Clinical studies showed that Lumigan 0.01% has similar efficacy to Lumigan 0.03%, *viz.*, IOP-lowering within 0.5 mmHg of that of Lumigan 0.03%, but it causes less frequent and severe hyperemia than Lumigan 0.03%. *Id.* at 20–21. In 2010, the FDA approved Allergan’s New Drug Application for Lumigan 0.01% for the same approved uses as Lumigan 0.03%.

II

Allergan owns the '504, '353, '118, '605, and '479 patents, which are all listed in the FDA's *Approved Drug Products with Therapeutic Equivalence Evaluations* (commonly known as the "Orange Book") as claiming Lumigan 0.01% and its approved uses. After Allergan received FDA-approval of Lumigan 0.01%, Sandoz, Lupin, Hi-Tech, and Watson each submitted an Abbreviated New Drug Application ("ANDA") to the FDA, seeking approval to engage in the commercial manufacture, use, importation, sale, or offer for sale of generic versions of Lumigan 0.01% prior to the expiration of the '504, '353, '118, '605, and '479 patents. In response, Allergan sued each of the ANDA applicants in the United States District Court for the Eastern District of Texas, asserting that their ANDA filings infringed those patents. The district court consolidated those actions into one case.

The asserted patents all derive from an application filed on March 16, 2005 and share a common specification. The patents are entitled "Enhanced Bimatoprost Ophthalmic Solution," '504 patent col. 1 ll. 1-2,³ and refer to what is Lumigan 0.03% in the background section, *id.* col. 1 ll. 34-36. The specifications of the patents describe a composition comprising 0.005% to 0.02% bimatoprost and 100 ppm to 250 ppm BAK, which is an aqueous liquid "formulated for ophthalmic administration" and "useful in treating glaucoma or ocular hypertension." *Id.* col. 1 ll. 61-67. The specifications also specifically describe a formulation comprising 0.01% bimatoprost and 200 ppm BAK, among other formulations, as a "best mode" of the invention. *Id.* col. 2 ll. 59, 64-67.

³ Because the asserted patents share an identical specification in relevant part, we refer only to the '504 patent when discussing the specifications of those patents.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.